You bring the big ideas, we bring highly specialized expertise in manual curation and disease map development to create new pathways quickly.
The MetaMiner program is a series of industry-academy partnerships on systems biology of common human diseases and stem cells, led by Thomson Reuters. For each disease, we reconstruct pathology and drug action pathways, assemble a database of molecular biomarkers and build a repository of annotated and statistically processed OMICs datasets. Development is guided by Directors, disease experts from pharmaceutical companies, government and academic institutions.
As well as working with a group of partners, we also offer exclusive partnerships solely with your company.
“GeneGo provides unique, innovative reconstructions of disease pathways that are fundamentally important and required for the understanding of disease processes so we can find cures.” Milka Sokolovic, PhD, Medical Biochemistry, Academic Medical Center, Amsterdam
With MetaMiner Partnerships, you can:
- Shape the landscape of your therapy area
- Get early access to new pathway maps that do not exist anywhere – giving you a competitive edge
- Speed up your discovery pipeline by having access to biomarker and drug repositories
- Create opportunities to develop and test hypotheses
- Direct and prioritize our efforts:
- Which journals and/or authors should be covered
- What pathway maps should be created and in what order of priority
- Gain a faster and easier understanding of the whole disease, rather than just your niche interest
Why choose MetaMiner Partnerships?
If you're ready to shape the landscape of your therapy area, but short of resources, a MetaMiner Partnership can help.
Over the last three years, we have formed several multi-year disease focused collaborations with leading pharmaceutical companies, non-profit foundations and expert academic groups. Partners often recommend specific companies or groups they'd like us to recruit who will add value and help shape the direction of the research.
With a MetaMiner Partnership, you gain access to:
- An established rigorous and successful manual curation process
- A team of annotators who are disease specialists dedicated to surveying the literature
- A team of high throughput data analysis for the data repository
- A team of signaling mechanism and map creators
- A collaborative environment with other scientists around the world
GeneGo, a Thomson Reuters business, is currently the only company manually curating true multi-step pathway maps backed by small experiment evidence.
Current partnerships include:
- Huntington's disease
- Multiple sclerosis
- Drug addiction
- Cystic Fibrosis
- Dry Eye
- Metabolic Diseases
- Diabetes II
- Metabolic syndrome X
- Breast cancer
- Colorectal cancer
- Hepatocellular carcinoma (HCC)
- Gastric Cancer
- Lung cancer
- Multiple myeloma
- Pancreatic cancer
- Respiratory Diseases
- Stem Cells
- Embryonic stem cells
- Adult stem cells in multiple tissues
- iP Stem cells
- Cancer stem cells
- Drug Mechanism of action
After a period of exclusivity the pathways developed through the partnerships are made available as modules of our data-mining and pathway analysis solution, MetaCore . Current MetaCore modules include: Gastric Cancer; Hepatocellular Carcinoma, Huntingdon's Disease, Pancreatic Cancer, Prostate Cancer and Stem Cells.
A fundamental understanding of human diseases is necessary for successful disease research, drug and biomarker discovery, translational medicine, and personalized health. Diseases represent abnormal states of the human organism, impacting dozens of processes and pathways. But reconstruction of disease mechanisms is a far from trivial endeavour, requiring technology and state-of-the-art domain expertise.
Over the last 5 years we have developed a systematic approach to disease reconstruction based on three pillars:
- Manual annotation of compound-disease, and gene-disease associations at DNA, RNA and protein level.
- Reconstruction of disease pathways, i.e. specific gain and loss of function changes
- Development of a data repository of statistically analysed Omics studies
Using a unique language to allow the inclusion of proteins (including fusion proteins, complexes, and isoforms), RNA, DNA, microRNA, and small molecules, and renowned for quality manually-curated content, on average we develop 12 step pathways and currently have the largest pathway map collection in the world, exceeding 2,000. Along with 12 (and counting) ontologies, you can ask complicated questions of our content and get the answers your research needs.
GSK joined the MetaMiner Partnership for Cystic Fibrosis (CF) and very quickly:
- Got up to speed in 6 months on a new disease that was not part of their therapeutic portfolio
- Improved screening hit rate from 1 percent to 19 percent
- Repositioned a drug that failed in clinical trials
Although the group had limited prior knowledge of CF, working with GeneGo, a Thomson Reuters business, with deliverables from a MetaMiner Partnership, they were able, in collaboration with an academic group with a novel trafficking assay, to identify a GSK drug with potential therapeutic activity. Having previously reached clinical trials for a different indication, this drug is ready to take into the clinic.
The complete process, from concept through target identification, screening, and confirmation took a mere 6 months. By prequalifying potential therapeutic targets through GeneGo content, and focusing screening on the most likely active compounds, they achieved a hit rate in the novel trafficking assay of 19 percent, compared to a more usual HTS hit rate of < 1 percent.
GSK scientists credit GeneGo with having a massive impact on this project, saving significant time and financial resources. The project has the potential to rescue millions of dollars spent on a failed drug, generate significant revenue from a previously unknown indication against cystic fibrosis, and provide critical clinical benefit to people suffering from this lethal and underserved disease.
Tel: +1 800.336.4474
Tel: +1 215.386.0100
Fax: +1 215.386.2911
Europe, Middle East & Africa
Tel: +44 20.7433.4000
Brazil: +55 11 8370 9845
Other Countries: +1 215 823 5674
Tel: +81 3.4589.3100
Tel: 0800 888.8855 (free dial from Japan only)
Fax: +81 3.4589.3240
Australia & New Zealand:
+61 2 8587 7636
China: +86 10 5760 1200
India: +91 11 3044 6419
Korea: +82 2 2076 8100
South East Asia & Pakistan:
+65 6775 5088
Taiwan: +886 2 2503 3034